CN114191446A - 含有白藜芦醇的抗疲劳药酒及其制备方法 - Google Patents
含有白藜芦醇的抗疲劳药酒及其制备方法 Download PDFInfo
- Publication number
- CN114191446A CN114191446A CN202210079257.5A CN202210079257A CN114191446A CN 114191446 A CN114191446 A CN 114191446A CN 202210079257 A CN202210079257 A CN 202210079257A CN 114191446 A CN114191446 A CN 114191446A
- Authority
- CN
- China
- Prior art keywords
- resveratrol
- cyclodextrin
- fatigue
- medicinal liquor
- liquor containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 title claims abstract description 81
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 title claims abstract description 81
- 235000021283 resveratrol Nutrition 0.000 title claims abstract description 81
- 229940016667 resveratrol Drugs 0.000 title claims abstract description 81
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229940088594 vitamin Drugs 0.000 claims abstract description 19
- 235000013343 vitamin Nutrition 0.000 claims abstract description 19
- 239000011782 vitamin Substances 0.000 claims abstract description 19
- 229930003231 vitamin Natural products 0.000 claims abstract description 19
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960000367 inositol Drugs 0.000 claims abstract description 18
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 18
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 18
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 18
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 18
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 18
- 241000219095 Vitis Species 0.000 claims abstract description 17
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 17
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 17
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 17
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 31
- 229920000858 Cyclodextrin Polymers 0.000 claims description 27
- 235000014101 wine Nutrition 0.000 claims description 20
- 229940024606 amino acid Drugs 0.000 claims description 18
- 235000001014 amino acid Nutrition 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 15
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 14
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical group CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 11
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 7
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- 239000001116 FEMA 4028 Substances 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- -1 aliphatic amino acids Chemical class 0.000 claims description 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 3
- 229960003121 arginine Drugs 0.000 claims description 3
- 235000009697 arginine Nutrition 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 3
- 229960004853 betadex Drugs 0.000 claims description 3
- 229960002433 cysteine Drugs 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 235000004554 glutamine Nutrition 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960003136 leucine Drugs 0.000 claims description 3
- 235000018977 lysine Nutrition 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 229960001153 serine Drugs 0.000 claims description 3
- 235000004400 serine Nutrition 0.000 claims description 3
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 3
- 229960003080 taurine Drugs 0.000 claims description 3
- 229960002898 threonine Drugs 0.000 claims description 3
- 235000008521 threonine Nutrition 0.000 claims description 3
- 229960004295 valine Drugs 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 229960002989 glutamic acid Drugs 0.000 claims 1
- 229960002743 glutamine Drugs 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 230000007721 medicinal effect Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 24
- 230000009182 swimming Effects 0.000 description 14
- 238000012549 training Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 9
- 206010016256 fatigue Diseases 0.000 description 8
- 238000002329 infrared spectrum Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- OEGPRYNGFWGMMV-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C=C1OC OEGPRYNGFWGMMV-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000020097 white wine Nutrition 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种含有白藜芦醇的抗疲劳药酒及其制备方法,包括葡萄蒸馏酒、白藜芦醇包合物、肌醇、烟酸、维生素,每100mL葡萄蒸馏酒含有200‑800mg白藜芦醇包合物、5mg‑15mg肌醇、1mg‑4mg烟酸、0.2mg‑0.8mg维生素,本发明制备的含有白藜芦醇的抗疲劳药酒,药酒中含有白藜芦醇的包合物、肌醇、烟酸、维生素,使得制备的药酒具有抗疲劳的效果;且制备的药酒中,添加的是白藜芦醇的包合物,不仅仅增加了药酒中抗疲劳的成分,而且使得白藜芦醇的水溶性与稳定性增加,不随时间的增长而分解,进而药酒的药效更好。
Description
技术领域
本发明涉及药酒制备技术领域,特别涉及一种含有白藜芦醇的抗疲劳药酒及其制备方法。
背景技术
随着社会的发展,生活压力、就业压力增加,越来越多的人在生活和工作中感到疲劳,疲劳是一种亚健康状态,严重影响生活质量。疲劳一方面可被机体主观感受,另一方面表现为机体体力或精力的减弱或丧失,是一种复杂的生理、心理现象。据WHO调查,全球有35%以上的人处于疲劳状态,中年男性人群疲劳状态达60%。疲劳发生后如果不能得到及时恢复,并且逐渐积累恶化,将可能导致“过劳”,内分泌紊乱、免疫力下降,继而出现“慢性疲劳综合征”、“过度训练综合症”等威胁人类健康的器质性疾病。
临床应用于缓解体力疲劳的药物和补品很多,现代研究表明白藜芦醇是一种非常重要的食品添加剂和预防医药用品,其对炎症、心血管疾病、抗疲劳方面有良好的效果,因此有必要提供一种抗疲劳药酒。
发明内容
有鉴于此,针对上述不足,有必要提出一种含有白藜芦醇的抗疲劳药酒。
还提出了一种含有白藜芦醇的抗疲劳药酒的制备方法。
一种含有白藜芦醇的抗疲劳药酒,包括葡萄蒸馏酒、白藜芦醇包合物、肌醇、烟酸、维生素,每100mL葡萄蒸馏酒含有200-800mg白藜芦醇包合物、5mg-15mg肌醇、1mg-4mg烟酸、0.2mg-0.8mg维生素。
优选地,所述白藜芦醇包合物选自白藜芦醇-环糊精或环糊精衍生物二元包合物、白藜芦醇-氨基酸-环糊精或环糊精衍生物三元包合物中的一种。
优选地,所述白藜芦醇-氨基酸-环糊精或环糊精衍生物三元包合物,包括白藜芦醇、氨基酸、环糊精或环糊精衍生物,所述白藜芦醇、氨基酸、环糊精或环糊精衍生物的摩尔比为1:1:1-10:10:1
优选地,所述氨基酸是脂肪族氨基酸。
优选地,所述环糊精衍生物为羟丙基-β-环糊精或磺丁基醚-β-环糊精。
优选地,所述环糊精选自a-环糊精、β-环糊精、γ-环糊精的一种。
优选地,所述氨基酸选自牛磺酸,γ-氨基丁酸,丙氨酸,缬氨酸,亮氨酸,异亮氨酸,蛋氨酸,甘氨酸,丝氨酸,苏氨酸,半胱氨酸,天冬酰胺,谷氨酰胺,赖氨酸,精氨酸,天冬氨酸,谷氨酸的一种。
优选地,所述维生素包括:VB6、VB12。
优选地,所述每100mL葡萄蒸馏酒含有VB60.1mg-0.4mg、VB120.1mg-0.4mg。
如上所述一种含有白藜芦醇的抗疲劳药酒的制备方法,其特征在于:将白藜芦醇包合物、肌醇、烟酸、维生素加入葡萄蒸馏酒中,每100mL葡萄蒸馏酒含有200-800mg白藜芦醇包合物、5mg-15mg肌醇、1mg-4mg烟酸、0.1mg-0.8mg维生素。
与现有技术相比,本发明的有益效果在于:
本发明制备的含有白藜芦醇的抗疲劳药酒,药酒中含有白藜芦醇的包合物、肌醇、烟酸、维生素,使得制备的药酒具有抗疲劳的效果;且制备的药酒中,添加的是白藜芦醇的包合物,不仅仅增加了药酒中抗疲劳的成分,而且使得白藜芦醇的稳定性增加,不随时间的增长而分解,进而药酒的药效更好。
并且以葡萄蒸馏酒作为基酒,相较白酒,葡萄蒸馏酒的口感、味道更好,人们饮用起来易入口。
附图说明
图1为白藜芦醇的红外图谱。
图2为γ-氨基丁酸的红外图谱的红外图谱。
图3为羟丙基-β-环糊精的红外图谱的红外图谱。
图4为白藜芦醇-氨基酸-羟丙基-β-环糊精物理混合物的红外图谱。
图5为白藜芦醇-氨基酸-羟丙基-β-环糊精三元包合物的红外图谱。
图6为实施例中包合物的稳定性曲线。
具体实施方式
为了更清楚地说明本发明实施例的技术方案,下面将对结合实施例作进一步的说明。
一种含有白藜芦醇的抗疲劳药酒,包括葡萄蒸馏酒、白藜芦醇包合物、肌醇、烟酸、维生素,每100mL葡萄蒸馏酒含有200-800mg白藜芦醇包合物、5mg-15mg肌醇、1mg-4mg烟酸、0.2mg-0.8mg维生素。
与现有技术相比,本发明的有益效果在于:
本发明制备的含有白藜芦醇的抗疲劳药酒,药酒中含有白藜芦醇的包合物、肌醇、烟酸、维生素,使得制备的药酒具有抗疲劳的效果;且制备的药酒中,添加的是白藜芦醇的包合物,不仅仅增加了药酒中抗疲劳的成分,而且使得白藜芦醇的水溶性与稳定性增加,不随时间的增长而分解,进而药酒的药效更好。
并且以葡萄蒸馏酒作为基酒,相较白酒,葡萄蒸馏酒的口感、味道更好,人们饮用起来易入口
进一步的,所述白藜芦醇包合物选自白藜芦醇-环糊精或环糊精衍生物二元包合物、白藜芦醇-氨基酸-环糊精或环糊精衍生物三元包合物中的一种。
进一步的,所述白藜芦醇-氨基酸-环糊精或环糊精衍生物三元包合物,包括白藜芦醇、氨基酸、环糊精或环糊精衍生物,所述白藜芦醇、氨基酸、环糊精或环糊精衍生物的摩尔比为1:1:1-10:10:1。
具体的,制备白藜芦醇-氨基酸-环糊精或环糊精衍生物三元包合物属于一个新的三元物系,属于新药分类中的2.1类新药;加入的氨基酸,使得形成的三元包合物的稳定常数更大,进而白藜芦醇被环糊精包合的更多,稳定性更好,使得药酒中的抗疲劳的成分更多,抗疲劳效果更好。
进一步的,所述白藜芦醇、氨基酸、环糊精或环糊精衍生物的摩尔比为1:1:1-2:2:1。
进一步的,所述氨基酸是脂肪族氨基酸。
进一步的,所述环糊精衍生物为羟丙基-β-环糊精或磺丁基醚-β-环糊精。
进一步的,所述环糊精选自a-环糊精、β-环糊精、γ-环糊精的一种。
进一步的,所述氨基酸选自牛磺酸,γ-氨基丁酸,丙氨酸,缬氨酸,亮氨酸,异亮氨酸,蛋氨酸,甘氨酸,丝氨酸,苏氨酸,半胱氨酸,天冬酰胺,谷氨酰胺,赖氨酸,精氨酸,天冬氨酸,谷氨酸的一种。
进一步的,所述维生素包括:VB6、VB12。
进一步的,所述每100mL葡萄蒸馏酒含有VB60.1mg-0.4mg、VB120.1mg-0.4mg。
一种含有白藜芦醇的抗疲劳药酒的制备方法,其特征在于:将白藜芦醇包合物、肌醇、烟酸、维生素加入葡萄蒸馏酒中,每100mL葡萄蒸馏酒含有200-800mg白藜芦醇包合物、5mg-15mg肌醇、1mg-4mg烟酸、0.1mg-0.8mg维生素。
具体的通过以下实施例具体说明。
实施例1:含有白藜芦醇-羟丙基-β-环糊精二元包合物的药酒的制备
取0.5mmol羟丙基-β-环糊精,加20mL水溶解,在室温下边搅拌边加入0.5mmol白藜芦醇、继续搅拌,使所述白藜芦醇和羟丙基-β-环糊精完全反应,待反应完成后,得到溶液,将上述溶液用微孔滤膜过滤,滤液在-80℃冰箱预冷冻4h,再用冷冻干燥机在-80℃干燥过夜得固体白藜芦醇-羟丙基-β-环糊精二元包合物,所述白藜芦醇-羟丙基-β-环糊精二元包合物的收率为80%以上。
药酒的制备:将白藜芦醇-羟丙基-β-环糊精二元包合物200mg、肌醇5mg、烟酸2mg、VB60.2mg、VB120.1mg加入100mL葡萄蒸馏酒中,得到含有白藜芦醇的抗疲劳药酒。
实施例2:含有白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物的药酒的制备:
白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物的制备:取0.5mmol羟丙基-β-环糊精,加20mL水溶解,在室温下边搅拌边加入0.5mmol白藜芦醇、0.5mmolγ-氨基丁酸,继续搅拌,使所述白藜芦醇、γ-氨基丁酸和羟丙基-β-环糊精完全反应,待反应完成后,得到溶液,将上述溶液用微孔滤膜过滤,滤液在-80℃冰箱预冷冻4h,再用冷冻干燥机在-80℃干燥过夜得固体白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物,所述白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物的收率为89%以上。
药酒的制备:将白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物200mg、肌醇5mg、烟酸2mg、VB60.2mg、VB120.1mg加入100mL葡萄蒸馏酒中,得到含有白藜芦醇的抗疲劳药酒。
对白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物进行表征:
图1至图3分为白藜芦醇、γ-氨基丁酸、羟丙基-β-环糊精的红外图谱,由图4白藜芦醇-氨基酸-羟丙基-β-环糊精物理混合物的红外吸收峰为:3400,2931,2184,1587,1460,1426,1401,1336,1308,1155,1083,1033,947,852,758,707,581;图5白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物的红外吸收峰:3393,2929,1589,1515,1455,1405,1264,1155,1083,1033,947,841,757,706,583。
由图4、图5可知,白藜芦醇-氨基酸-羟丙基-β-环糊精物理混合物和白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物对比,白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物红外光谱的吸收峰有些发生红移,白藜芦醇-氨基酸-羟丙基-β-环糊精物理混合物红外光谱的吸收峰有些吸收强度变弱,有的甚至消失,进而证明白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物的形成。
请参看图6,将白藜芦醇、白藜芦醇-羟丙基-β-环糊精二元包合物、白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物进行365nm光照稳定性实验,可知白藜芦醇单体、白藜芦醇-羟丙基-β-环糊精二元包合物与白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物之间对比,在365nm光照条件下,白藜芦醇单体降解最多,最不稳定;二元包合物、三元包合物较白藜芦醇单体更加稳定,且三元包合物降解最少,最稳定。
将得到的白藜芦醇-羟丙基-β-环糊精二元包合物、白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物进行溶解度检测:
1.将得到的白藜芦醇-羟丙基-β-环糊精二元包合物,采用相溶解度法,计算羟丙基-β-环糊精对白藜芦醇的增溶倍数,发现白藜芦醇的最大溶解度提高了近40倍以上,(S=0.0140g/L,S1’=0.5800g/L)。
2.将得到的白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物,采用相溶解度法,计算氨基酸与羟丙基-β-环糊精对白藜芦醇的增溶倍数,发现白藜芦醇的最大溶解度提高了近83倍以上,(S=0.0140g/L,S2’=1.1700g/L)。
因药酒的酒精含量均具有一定度数,不能直接对小鼠进行灌胃,小鼠容易晕倒,因此将药酒中的有效成分进行抗疲劳效果试验,故将实施例得到的包合物进行抗疲劳效果试验:
选取无特定病原体级(SPF级)雄性小鼠65只,4周龄,体重(20±2)g,将小鼠常规饲养3天,适应性游泳3天后,淘汰个别不适应游泳训练的小鼠,最终选取60只小鼠随机分为4组,每组15只。A组为正常饲养小鼠进行游泳训练,B组为灌胃白藜芦醇小鼠进行游泳训练;C组为灌胃白藜芦醇-羟丙基-β-环糊精二元包合物小鼠进行游泳训练;D组为灌胃白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物小鼠进行游泳训练。
各组小鼠自由进水进食,每日下午13时B组的小鼠灌胃白藜芦醇10mg/kg、C组小鼠为灌胃白藜芦醇-羟丙基-β-环糊精二元包合物(折算成白藜芦醇)10mg/kg、D组的小鼠灌胃白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物(折算成白藜芦醇)10mg/kg,A组小鼠用等体积蒸馏水灌胃,按照上述标准对各组小鼠连续灌胃6周。
在6周内,A、B、C和D组小鼠游泳训练时间从20min起,每隔2天游泳时间递增5min,每周训练5天,休息1天,共6周,具体训练时间安排如表1所示,小鼠每天训练2次,开始时间为上午9时和下午15时。
末次给予药物30min后,将小鼠置于游泳想中游泳至力竭,记录游泳时间。力竭判断标准:小鼠沉入水下超过10s不能自行浮出,四肢运动不协调,置于台面上不能做翻转动作,可判断为力竭。
表1小鼠的计划游泳训练时间安排
注′为分钟。
表2白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物对游泳训练小鼠运动耐力的影响
分组 | N(小鼠个数) | 力竭平均时间/min |
A训练组 | 15 | 237±38 |
B白藜芦醇单体组 | 15 | 314±42<sup>*</sup> |
C二元包合物组 | 15 | 396±45<sup>#</sup> |
D三元包合物组 | 15 | 431±47<sup>Δ</sup> |
与A组比较*P<0.05;与B组比较#P<0.05;与B组比较ΔP<0.01。
综上所述,在训练强度相同的情况下,A组与B组对比,B组对小鼠灌胃白藜芦醇,B组的小鼠的游泳时间增长,说明白藜芦醇增强小鼠的游泳运动能力;B组与C组对比,C组对小鼠灌胃白藜芦醇-羟丙基-β-环糊精二元包合物,小鼠力竭的时间更长,说明白藜芦醇-羟丙基-β-环糊精二元包合物使得小鼠游泳运动能力增强;C组与D组对比,D组对小鼠灌胃白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物,小鼠力竭的时间更长,说明白藜芦醇-γ-氨基丁酸-羟丙基-β-环糊精三元包合物相较于白藜芦醇-羟丙基-β-环糊精二元包合物,小鼠游泳运动能力更强;因此包合物能够增强小鼠的运动能力,进而能够增强抗疲劳效果,则制得的药酒也具有此效果。
以上所揭露的仅为本发明较佳实施例而已,当然不能以此来限定本发明之权利范围,本领域普通技术人员可以理解实现上述实施例的全部或部分流程,并依本发明权利要求所作的等同变化,仍属于发明所涵盖的范围。
Claims (10)
1.一种含有白藜芦醇的抗疲劳药酒,其特征在于:包括葡萄蒸馏酒、白藜芦醇包合物、肌醇、烟酸、维生素,每100mL葡萄蒸馏酒含有200-800mg白藜芦醇包合物、5mg-15mg肌醇、1mg-4mg烟酸、0.2mg-0.8mg维生素。
2.如权利要求1所述的含有白藜芦醇的抗疲劳药酒,其特征在于:所述白藜芦醇包合物选自白藜芦醇-环糊精或环糊精衍生物二元包合物、白藜芦醇-氨基酸-环糊精或环糊精衍生物三元包合物中的一种。
3.如权利要求2所述的含有白藜芦醇的抗疲劳药酒,其特征在于:所述白藜芦醇-氨基酸-环糊精或环糊精衍生物三元包合物,包括白藜芦醇、氨基酸、环糊精或环糊精衍生物,所述白藜芦醇、氨基酸、环糊精或环糊精衍生物的摩尔比为1:1:1-10:10:1。
4.如权利要求3所述的含有白藜芦醇的抗疲劳药酒,其特征在于:所述氨基酸是脂肪族氨基酸。
5.如权利要求3所述的含有白藜芦醇的抗疲劳药酒,其特征在于:所述环糊精衍生物为羟丙基-β-环糊精或磺丁基醚-β-环糊精。
6.如权利要求3所述的含有白藜芦醇的抗疲劳药酒,其特征在于:所述环糊精选自a-环糊精、β-环糊精、γ-环糊精的一种。
7.如权利要求3所述的含有白藜芦醇的抗疲劳药酒,其特征在于:所述氨基酸选自牛磺酸,γ-氨基丁酸,丙氨酸,缬氨酸,亮氨酸,异亮氨酸,蛋氨酸,甘氨酸,丝氨酸,苏氨酸,半胱氨酸,天冬酰胺,谷氨酰胺,赖氨酸,精氨酸,天冬氨酸,谷氨酸的一种。
8.如权利要求1所述的含有白藜芦醇的抗疲劳药酒,其特征在于:所述维生素包括:VB6、VB12。
9.如权利要求8所述的含有白藜芦醇的抗疲劳药酒,其特征在于:所述每100mL葡萄蒸馏酒含有0.1mg-0.4mg的VB6、0.1mg-0.4mg的VB12。
10.如权利要求1-9任意一项所述一种含有白藜芦醇的抗疲劳药酒的制备方法,其特征在于:将白藜芦醇包合物、肌醇、烟酸、维生素加入葡萄蒸馏酒中,每100mL葡萄蒸馏酒含有200-800mg白藜芦醇包合物、5mg-15mg肌醇、1mg-4mg烟酸、0.1mg-0.8mg维生素。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210079257.5A CN114191446B (zh) | 2022-01-24 | 2022-01-24 | 含有白藜芦醇的抗疲劳药酒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210079257.5A CN114191446B (zh) | 2022-01-24 | 2022-01-24 | 含有白藜芦醇的抗疲劳药酒及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114191446A true CN114191446A (zh) | 2022-03-18 |
CN114191446B CN114191446B (zh) | 2023-12-29 |
Family
ID=80658768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210079257.5A Active CN114191446B (zh) | 2022-01-24 | 2022-01-24 | 含有白藜芦醇的抗疲劳药酒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114191446B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115177603A (zh) * | 2022-06-21 | 2022-10-14 | 宁夏医科大学 | 白藜芦醇-环糊精复合物的制备方法及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1850960A (zh) * | 2006-03-02 | 2006-10-25 | 陕西省科学院酶工程研究所 | 一种营养茶酒的酿造工艺 |
KR20100006359A (ko) * | 2008-07-09 | 2010-01-19 | (주)미모아 | 하이드록시 프로필 사이클로덱스트린-레스베라트롤포접체를 함유하는 화장료 조성물 |
CN104877845A (zh) * | 2015-06-24 | 2015-09-02 | 陈星宏 | 一种高纯正葡萄酒生产工艺 |
CN107029248A (zh) * | 2017-04-22 | 2017-08-11 | 湖北省三鑫生物科技有限公司 | 白藜芦醇固体分散体及增加白藜芦醇在红酒中的溶解度的方法 |
CN112843025A (zh) * | 2021-03-22 | 2021-05-28 | 曲阜师范大学 | 一种白藜芦醇营养补充剂的制备方法 |
-
2022
- 2022-01-24 CN CN202210079257.5A patent/CN114191446B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1850960A (zh) * | 2006-03-02 | 2006-10-25 | 陕西省科学院酶工程研究所 | 一种营养茶酒的酿造工艺 |
KR20100006359A (ko) * | 2008-07-09 | 2010-01-19 | (주)미모아 | 하이드록시 프로필 사이클로덱스트린-레스베라트롤포접체를 함유하는 화장료 조성물 |
CN104877845A (zh) * | 2015-06-24 | 2015-09-02 | 陈星宏 | 一种高纯正葡萄酒生产工艺 |
CN107029248A (zh) * | 2017-04-22 | 2017-08-11 | 湖北省三鑫生物科技有限公司 | 白藜芦醇固体分散体及增加白藜芦醇在红酒中的溶解度的方法 |
CN112843025A (zh) * | 2021-03-22 | 2021-05-28 | 曲阜师范大学 | 一种白藜芦醇营养补充剂的制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115177603A (zh) * | 2022-06-21 | 2022-10-14 | 宁夏医科大学 | 白藜芦醇-环糊精复合物的制备方法及其应用 |
CN115177603B (zh) * | 2022-06-21 | 2024-08-13 | 宁夏医科大学 | 白藜芦醇-环糊精复合物的制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114191446B (zh) | 2023-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE1006186A3 (fr) | Produits pharmaceutiques pour guerir des maladies tumorales et procede pour les preparer. | |
CN114191446A (zh) | 含有白藜芦醇的抗疲劳药酒及其制备方法 | |
FR2502953A1 (fr) | Association de produits constituant un medicament empechant la formation de depots graisseux chez les mammiferes | |
WO2013021891A1 (ja) | 筋肉疲労の回復を促進するためのアミノ酸含有組成物 | |
EP2143434A1 (en) | Composition for promoting ketone compound formation | |
US20140037770A1 (en) | Burdock Fruit Extract Containing Arctigenin and Method for Producing Same | |
CN114225049B (zh) | 白藜芦醇-氨基酸-环糊精或环糊精衍生物三元包合物及组合物及制备方法及用途 | |
EP0796238B1 (fr) | Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises en therapeutique et en cosmetologie | |
EP2455088B1 (en) | Inhibitor of blood triglyceride level elevation | |
JP6710098B2 (ja) | 栄養剤組成物及び栄養補助食品 | |
CN110709086A (zh) | 动脉血血氧饱和度的提高剂 | |
JPH07233061A (ja) | 人を含む動物の悪性腫瘍細胞増殖抑制作用を有する経口投与剤の製造方法 | |
US20220046960A1 (en) | Beverage composition and process | |
KR20160081436A (ko) | 레스베라트롤이 강화된 땅콩나물을 유효성분으로 함유하는 피로회복 또는 운동기능 증강용 식품 조성물 | |
US20080254016A1 (en) | Composition For Increasing Anti-Oxidation Activity In Blood | |
JP4887052B2 (ja) | 発声改良剤および発声改良方法 | |
US20230270770A1 (en) | Nutritional supplements for repairing muscle and defending against deterioration from human aging | |
US20060105965A1 (en) | Method for enhancing energy levels and reducing the effects of stress using nutraceutical formulations | |
KR101655882B1 (ko) | 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 숙취해소용 조성물 | |
FR2643081A1 (fr) | Folates de magnesium, procede de preparation et compositions pharmaceutiques | |
FR2953688A3 (fr) | Composition contenant des polyphenols de grenade, de la vitamine d et des oligoelements. | |
RU2174547C1 (ru) | Способ производства водки | |
RU2174542C1 (ru) | Способ производства водки | |
RU2174544C1 (ru) | Способ производства водки | |
KR101931442B1 (ko) | 항산화 또는 항염증 활성을 나타내는 신규 화합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |